{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T03:19:09Z","timestamp":1776741549351,"version":"3.51.2"},"reference-count":57,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.ymthe.2025.05.003","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T14:37:14Z","timestamp":1746715034000},"page":"3789-3807","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["FLT201, a novel liver-directed AAV gene therapy candidate for Gaucher disease type 1"],"prefix":"10.1016","volume":"33","author":[{"given":"Fabrizio","family":"Comper","sequence":"first","affiliation":[]},{"given":"Carlos J.","family":"Miranda","sequence":"additional","affiliation":[]},{"given":"Benjamin","family":"Liou","sequence":"additional","affiliation":[]},{"given":"Tihomir","family":"Dodev","sequence":"additional","affiliation":[]},{"given":"Jey M.","family":"Jeyakumar","sequence":"additional","affiliation":[]},{"given":"Miriam","family":"Canavese","sequence":"additional","affiliation":[]},{"given":"Clement","family":"Cocita","sequence":"additional","affiliation":[]},{"given":"Khashayar","family":"Khoshrou","sequence":"additional","affiliation":[]},{"given":"Gustavo","family":"Tiscornia","sequence":"additional","affiliation":[]},{"given":"Elisa","family":"Chisari","sequence":"additional","affiliation":[]},{"given":"Emmaline","family":"Stotter","sequence":"additional","affiliation":[]},{"given":"Erald","family":"Shehu","sequence":"additional","affiliation":[]},{"given":"Sudharsan","family":"Sridharan","sequence":"additional","affiliation":[]},{"given":"I-Mei","family":"Yu","sequence":"additional","affiliation":[]},{"given":"Jalpa","family":"Pandya","sequence":"additional","affiliation":[]},{"given":"Jaminder","family":"Khinder","sequence":"additional","affiliation":[]},{"given":"Natalie","family":"Northcott","sequence":"additional","affiliation":[]},{"given":"Petya","family":"Kalcheva","sequence":"additional","affiliation":[]},{"given":"Samantha","family":"Correia","sequence":"additional","affiliation":[]},{"given":"Ying","family":"Sun","sequence":"additional","affiliation":[]},{"given":"Allison P.","family":"Dane","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6773-7082","authenticated-orcid":false,"given":"Rose","family":"Sheridan","sequence":"additional","affiliation":[]},{"given":"Amit C.","family":"Nathwani","sequence":"additional","affiliation":[]},{"given":"Romuald","family":"Corbau","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2025.05.003_bib1","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3390\/ijms18020441","article-title":"A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments","volume":"18","author":"Stirnemann","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2025.05.003_bib2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/10245332.2016.1240391","article-title":"Gaucher disease epidemiology and natural history: a comprehensive review of the literature","volume":"22","author":"Nalysnyk","year":"2017","journal-title":"Hematology"},{"key":"10.1016\/j.ymthe.2025.05.003_bib3","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1001\/archinte.160.18.2835","article-title":"The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease","volume":"160","author":"Charrow","year":"2000","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.ymthe.2025.05.003_bib4","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","article-title":"Replacement Therapy for Inherited Enzyme Deficiency \u2014 Macrophage-Targeted Glucocerebrosidase for Gaucher\u2019s Disease","volume":"324","author":"Barton","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.05.003_bib5","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/17446651.2018.1445524","article-title":"Recent advances in the diagnosis and management of Gaucher disease","volume":"13","author":"Gary","year":"2018","journal-title":"Expert Rev. Endocrinol. Metab."},{"key":"10.1016\/j.ymthe.2025.05.003_bib6","series-title":"GeneReviews\u00ae [Internet]","first-page":"1993","article-title":"[Updated 2023 Dec 7]. Gaucher Disease","author":"Hughes","year":"2000"},{"key":"10.1016\/j.ymthe.2025.05.003_bib7","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ejmhg.2016.02.001","article-title":"Treatment options for patients with Gaucher disease","volume":"17","author":"Shawky","year":"2016","journal-title":"Egypt. J. Med. Hum. Genet."},{"key":"10.1016\/j.ymthe.2025.05.003_bib8","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s10545-012-9528-4","article-title":"Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment","volume":"36","author":"Weinreb","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymthe.2025.05.003_bib9","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ymgme.2020.12.295","article-title":"Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment","volume":"132","author":"Weinreb","year":"2021","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2025.05.003_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta16390","article-title":"The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders","volume":"16","author":"Wyatt","year":"2012","journal-title":"Health Technol. Assess."},{"key":"10.1016\/j.ymthe.2025.05.003_bib11","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1651-2227.2008.00653.x","article-title":"Gaucher disease: unmet treatment needs","volume":"97","author":"Mehta","year":"2008","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.ymthe.2025.05.003_bib12","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3390\/biom11040611","article-title":"Gene Therapy for Lysosomal Storage Disorders: Ongoing Studies and Clinical Development","volume":"11","author":"Massaro","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.ymthe.2025.05.003_bib13","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1080\/14712598.2019.1607837","article-title":"An update on gene therapy for lysosomal storage disorders","volume":"19","author":"Nagree","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.ymthe.2025.05.003_bib14","first-page":"81","article-title":"Imiglucerase in the treatment of Gaucher disease: a history and perspective","volume":"6","author":"Deegan","year":"2012","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ymthe.2025.05.003_bib15","doi-asserted-by":"crossref","first-page":"e00071","DOI":"10.1042\/BSR20130081","article-title":"Glycosylation and functionality of recombinant \u03b2-glucocerebrosidase from various production systems","volume":"33","author":"Tekoah","year":"2013","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.ymthe.2025.05.003_bib16","article-title":"Comparative Therapeutic Effects of Velaglucerase Alfa and Imiglucerase in a Gaucher Disease Mouse Model","volume":"5","author":"Xu","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2025.05.003_bib17","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1056\/NEJMoa2119913","article-title":"Phase 1\u20132 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B","volume":"387","author":"Chowdary","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.05.003_bib18","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1182\/blood-2005-10-4035","article-title":"Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver","volume":"107","author":"Nathwani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.05.003_bib19","article-title":"Gene Therapy Advances: A Meta-Analysis of AAV Usage in Clinical Settings","volume":"8","author":"Au","year":"2021","journal-title":"Front. Med."},{"key":"10.1016\/j.ymthe.2025.05.003_bib20","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1006\/mthe.2000.0075","article-title":"Inclusion of the Hepatic Locus Control Region, an Intron, and Untranslated Region Increases and Stabilizes Hepatic Factor IX Gene Expression in Vivo but Not in Vitro","volume":"1","author":"Miao","year":"2000","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.05.003_bib21","doi-asserted-by":"crossref","first-page":"22577","DOI":"10.1074\/jbc.270.38.22577","article-title":"Structure of the Hepatic Control Region of the Human Apolipoprotein E\/C-I Gene Locus","volume":"270","author":"Dang","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymthe.2025.05.003_bib22","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1182\/blood.V84.10.3394.bloodjournal84103394","article-title":"Quantitative evaluation of liver-specific promoters from retroviral vectors after in vivo transduction of hepatocytes","volume":"84","author":"Hafenrichter","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.05.003_bib23","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/j.ymgme.2021.11.142","article-title":"Design of GALILEO-1, a phase 1\/2 safety and efficacy study of FLT201 in adult patients with Gaucher disease type 1","volume":"135","author":"Hughes","year":"2022","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2025.05.003_bib24","first-page":"1","year":"2024"},{"key":"10.1016\/j.ymthe.2025.05.003_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-98611-7","article-title":"The mannose receptor (CD206) identifies a population of colonic macrophages in health and inflammatory bowel disease","volume":"11","author":"Wright","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2025.05.003_bib26","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.immuni.2020.12.003","article-title":"Distinct developmental pathways from blood monocytes generate human lung macrophage diversity","volume":"54","author":"Evren","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2025.05.003_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102735","article-title":"Systemic enzyme delivery by blood-brain barrier-penetrating SapC-DOPS nanovesicles for treatment of neuronopathic Gaucher disease","volume":"55","author":"Sun","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ymthe.2025.05.003_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0170268","article-title":"Investigations on therapeutic glucocerebrosidases through paired detection with fluorescent activity-based probes","volume":"12","author":"Kallemeijn","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2025.05.003_bib29","series-title":"Safety and efficacy of FLT190 for the treatment of patients with Fabry disease: Results from the MARVEL-1 Phase 1\/2 clinical trial Paper Presented at the 18th Annual WORLD Symposium;","author":"Hughes","year":"2022"},{"key":"10.1016\/j.ymthe.2025.05.003_bib30","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1089\/humc.2019.030","article-title":"The Influence of Murine Genetic Background in Adeno-Associated Virus Transduction of the Mouse Brain","volume":"30","author":"He","year":"2019","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.05.003_bib31","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1203\/00006450-199205000-00018","article-title":"Enzyme Augmentation in Moderate to Life-Threatening Gaucher Disease","volume":"31","author":"Fallet","year":"1992","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ymthe.2025.05.003_bib32","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/0046-8177(95)90097-7","article-title":"Pathological findings in gaucher disease type 2 patients following enzyme therapy\u22171","volume":"26","author":"Bove","year":"1995","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ymthe.2025.05.003_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0010021","article-title":"Enzyme Replacement in Gaucher Disease","volume":"1","author":"Beutler","year":"2004","journal-title":"Plos Med."},{"key":"10.1016\/j.ymthe.2025.05.003_bib34","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJM199212033272304","article-title":"A Less Costly Regimen of Alglucerase to Treat Gaucher\u2019s Disease","volume":"327","author":"Figueroa","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.05.003_bib35","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood.V78.5.1183.1183","article-title":"Enzyme replacement therapy for Gaucher disease","volume":"78","author":"Beutler","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.05.003_bib36","doi-asserted-by":"crossref","DOI":"10.1177\/2326409816650465","article-title":"Lysosomes, Lysosomal Storage Diseases, and Inflammation","volume":"4","author":"Simonaro","year":"2016","journal-title":"J. Inborn Errors Metab. Screen."},{"key":"10.1016\/j.ymthe.2025.05.003_bib37","doi-asserted-by":"crossref","first-page":"S183","DOI":"10.3233\/JPD-212739","article-title":"Gene Therapy for Parkinson\u2019s Disease Associated with GBA1 Mutations","volume":"11","author":"Abeliovich","year":"2021","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.ymthe.2025.05.003_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2024.108873","article-title":"Phase 1\/2 dose-finding study to evaluate systemic administration of an AAV9-based gene therapy for peripheral manifestation of Gaucher disease: The PROCEED study","volume":"144","author":"Neuhaus","year":"2025","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2025.05.003_bib39","doi-asserted-by":"crossref","first-page":"13819","DOI":"10.1073\/pnas.0606016103","article-title":"Effective cell and gene therapy in a murine model of Gaucher disease","volume":"103","author":"Enquist","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.05.003_bib40","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.omtm.2020.11.018","article-title":"Correction of pathology in mice displaying Gaucher disease type 1 by a clinically-applicable lentiviral vector","volume":"20","author":"Dahl","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2025.05.003_bib41","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/j.ymgme.2019.11.168","article-title":"Gene therapy PR001 increased GCase activity and improved neuronopathic Gaucher disease phenotypes in mouse models","volume":"129","author":"Heckman","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2025.05.003_bib42","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41434-022-00381-y","article-title":"Preclinical evaluation of FLT190, a liver-directed AAV gene therapy for Fabry disease","volume":"30","author":"Jeyakumar","year":"2023","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.05.003_bib43","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1038\/mt.2011.119","article-title":"Systemic Administration of AAV8-a-galactosidase A Induces Humoral Tolerance in Nonhuman Primates Despite Low Hepatic Expression","volume":"19","author":"Nietupski","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.05.003_bib44","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1038\/mt.2010.175","article-title":"Preexisting Immunity and Low Expression in Primates Highlight Translational Challenges for Liver-directed AAV8-mediated Gene Therapy","volume":"18","author":"Hurlbut","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.05.003_bib45","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.bcmd.2016.03.004","article-title":"Development of anti-velaglucerase alfa antibodies in clinical trial-treated patients with Gaucher disease","volume":"59","author":"Pastores","year":"2016","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ymthe.2025.05.003_bib46","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1172\/JCI200316887","article-title":"Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer","volume":"111","author":"Mingozzi","year":"2003","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2025.05.003_bib47","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1182\/blood-2007-02-073304","article-title":"Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer","volume":"110","author":"Cao","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.05.003_bib48","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1182\/blood-2007-03-080093","article-title":"Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver","volume":"110","author":"Mingozzi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2025.05.003_bib49","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41434-023-00410-4","article-title":"Preclinical safety and biodistribution of CRISPR targeting SIV in non-human primates","volume":"31","author":"Burdo","year":"2024","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.05.003_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2024.108945","article-title":"Results from GALILEO1, a first in human clinical trial of FLT201 AAV-gene therapy in adult patients with Gaucher disease type 1","volume":"144","author":"Sharma","year":"2025","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2025.05.003_bib51","doi-asserted-by":"crossref","first-page":"W126","DOI":"10.1093\/nar\/gkm219","article-title":"OPTIMIZER: a web server for optimizing the codon usage of DNA sequences","volume":"35","author":"Puigb\u00f2","year":"2007","journal-title":"Nucleic Acids Res. Suppl."},{"key":"10.1016\/j.ymthe.2025.05.003_bib52","first-page":"334","article-title":"Improved Two-Plasmid Packaging System for Manufacturing of AAV Vectors with High Quality and Consistency","volume":"27","author":"Schulze","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.05.003_bib53","first-page":"698","article-title":"A Robust Commercial rAAV-Vector Platform Process Using the iCELLis\u00ae 500 Fixed-Bed Bioreactor","volume":"27","author":"Carli","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.05.003_bib56","doi-asserted-by":"crossref","first-page":"D339","DOI":"10.1093\/nar\/gky1006","article-title":"The Immune Epitope Database (IEDB): 2018 update","volume":"47","author":"Vita","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.ymthe.2025.05.003_bib57","series-title":"HLA allele frequencies and reference sets with maximal population","author":"Martini","year":"2020"},{"key":"10.1016\/j.ymthe.2025.05.003_bib54","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0002-9440(10)63566-3","article-title":"Viable Mouse Models of Acid \u03b2-Glucosidase Deficiency","volume":"163","author":"Xu","year":"2003","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ymthe.2025.05.003_bib55","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0252325","article-title":"Decreased glucocerebrosidase activity and substrate accumulation of glycosphingolipids in a novel GBA1 D409V knock-in mouse model","volume":"16","author":"Polinski","year":"2021","journal-title":"PLoS One"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625003727?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625003727?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:42:02Z","timestamp":1762548122000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001625003727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":57,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S1525001625003727"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.05.003","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FLT201, a novel liver-directed AAV gene therapy candidate for Gaucher disease type 1","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}